NeuroPace, Inc. (NPCE)
| Market Cap | 465.04M +57.9% |
| Revenue (ttm) | 99.53M +18.1% |
| Net Income | -21.57M |
| EPS | -0.65 |
| Shares Out | 34.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 366,136 |
| Open | 14.60 |
| Previous Close | 15.31 |
| Day's Range | 13.42 - 14.94 |
| 52-Week Range | 7.56 - 19.60 |
| Beta | 1.89 |
| Analysts | Strong Buy |
| Price Target | 20.22 (+48.24%) |
| Earnings Date | Aug 11, 2026 |
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programmin... [Read more]
Financial Performance
In 2025, NeuroPace's revenue was $99.99 million, an increase of 25.13% compared to the previous year's $79.91 million. Losses were -$21.47 million, -20.91% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $20.22, which is an increase of 48.24% from the latest price.
News
NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
NeuroPace (NPCE) on Tuesday provided an update on the U.S. Food and Drug Administration review of the company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for…
NeuroPace Transcript: FDA announcement
FDA found the PMA supplement for RNS System expansion to drug-resistant IGE not approvable as submitted, requesting more clinical data but willing to collaborate. NAUTILUS trial data show strong safety/efficacy. The company will submit more info via SIR; no new trials required. Review timelines may not reset; financial guidance unchanged.
NeuroPace Press release: FDA announcement
NeuroPace issued a press release on July 28, 2026, disclosing material business information to investors.
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. ...
NeuroPace initiated with an Outperform at Mizuho
Mizuho initiated coverage of NeuroPace (NPCE) with an Outperform rating and $22 price target The firm’s neurology survey indicates “significant upside potential” for the company’s responsive neurostim...
NeuroPace Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and governance procedures. Both proposals passed with strong support, and no questions were raised by shareholders. Forward-looking statements and risk factors were acknowledged.
NeuroPace announces FDA approval of ECoG Assistant
NeuroPace (NPCE) announced FDA approval of ECoG Assistant. This milestone represents an important step in NeuroPace’s broader AI platform strategy. “This approval underscores how NeuroPace’s data adva...
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will...
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG ...
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on NeuroPace (NPCE) to $20 from $19 and keeps a Buy rating on the shares following quarterly results. According to management, the company…
NeuroPace reports Q1 EPS (20c), consensus (23c)
Reports Q1 revenue $22.1M, consensus $21.7M. “First quarter results reflect continued execution against the strategic priorities we outlined earlier this year,” said Joel Becker, Chief Executive Offic...
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
Consensus $98.9M. Reiterates FY26 gross margin between 81.5% and 82.5% and increases Adjusted EBITDA to ($8.5M) and ($9.5M) compared to previous guidance between ($9.0M) to ($10.0M).
NeuroPace Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% revenue growth, record patient pipeline, and raised full-year guidance to $99–$101 million, driven by strong RNS System adoption and expanding community referrals. Clinical and AI product development advanced, while IGE indication expansion remains excluded from guidance.
NeuroPace Earnings release: Q1 2026
NeuroPace released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
NeuroPace Quarterly report: Q1 2026
NeuroPace has published its Q1 2026 quarterly earnings report on May 12, 2026.
NeuroPace Slides: Q1 2026
NeuroPace has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ...
NeuroPace announces publication of 3-year results from RNS System PAS
NeuroPace (NPCE) announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS System Post-Approval Study, PAS, in Neurology, alongside the Company’s...
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a majo...
NeuroPace Proxy statement: Proxy filing
NeuroPace filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
NeuroPace Proxy statement: Proxy filing
NeuroPace filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
NeuroPace Transcript: 25th Annual Needham Virtual Healthcare Conference
The company reported strong 2025 growth, reaching $100 million in revenue and expanding its patient base. Key initiatives include FDA submission for IGE indication, AI-driven product enhancements, and a broadened sales force. 2026 is expected to be transformational, with further market and clinical expansion.
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace assumed with an Overweight at Wells Fargo
Wells Fargo assumed coverage of NeuroPace (NPCE) with an Overweight rating and $19 price target The firm is maintaining the current rating, price target and estimates.